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Since the early 2000s, the number of diabetes drugs has more than doubled and over 20 
cardiovascular or renal outcome trials have completed. This new evidence has accrued at 
such a rapid rate that many health care professionals are struggling to keep up. Guideline and 
consensus committees are tasked with summarising the evidence in a manner that is balanced, 
easily digestible and practical. 
The 2018 American Diabetes Association (ADA) / European Association for the Study of 
Diabetes (EASD) consensus report emphasized patient-centred care along with 
recommendations to select specific antihyperglycemic therapy, after metformin, based on the 
cardiovascular / renal status of patients.1 In individuals with existing atherosclerotic 
cardiovascular disease (ASCVD), the ADA/EASD supported the use of either a sodium 
glucose cotransporter-2 inhibitor (SGLT2i) or glucagon-like-peptide-1 receptor agonist 
(GLP-1RA) to lessen the risk of major adverse cardiovascular event (MACE), whereas in 
those with heart failure (HF) or chronic kidney disease (CKD), a SGLT2i was recommended.. 
Metformin remained first-line therapy and the addition of other therapy was recommended 
only if the HbA1c target was not achieved. 
In September 2019, the European Society of Cardiology (ESC) published guidelines on 
diabetes, prediabetes and cardiovascular disease in collaboration with the EASD.2 This 
document included two fundamental differences. First, it recommended that either a SGLT2i 
or a GLP-1RA be prescribed in treatment-naïve patients with T2D and ASCVD, without 
having to start metformin first. Secondly, the recommendation that a SGLT2i or a GLP-1RA 
should be prescribed, regardless of HbA1c level, as the cardiovascular benefits of these drugs 
are independent of HbA1c. The guideline further challenged orthodoxy in recommending 
these therapies be preferentially used not just in those with ASCVD but also in those deemed 
to be at ‘very high’ or ‘high’ risk of CV disease, using broad definitions that encompass a 
sizeable proportion of patients with T2D. 
The ADA/EASD 2018 consensus report has just been updated with some notable changes.3 
Firstly, in patients with ASCVD, HF or CKD, the use of diabetes therapies proven to reduce 
risk should not be contingent on HbA1c levels, in recognition of the glucose-independent CV 
and renal benefits of these therapies, bringing consistency with the ESC-led guidelines. 
However, the ADA/EASD report continues to maintain the primacy of metformin. A further 
change in the ADA/EASD update is the recommendation that a SGLT2i or a GLP-1RA 
should also be prescribed in patients with “indicators of high CV risk”; defined as age over 
55 years with “coronary, carotid, or lower extremity artery stenosis exceeding 50%, left 
ventricular hypertrophy, estimated glomerular filtration rate (eGFR) less than 60 mL/min per 
1.73 m², or albuminuria”, based on previous trials. Another important change is the favouring 
of GLP-1RA for those with ASCVD or with “indicators of high CV risk”, on the basis that 
the trial evidence was interpreted as showing GLP-1RA reduce MACE in these patients, 
considered by the authors to be the ‘gravest threat’. SGLT2i reduced MACE only in those 
with ASCVD, although  reduced hospitalization for heart failure and renal outcomes in 
patients with either ASCVD or “indicators of high CV risk”.4 Finally, this new update 
provides more detailed criteria for the type of HF (reduced ejection fraction) and definitions 
of CKD where a SGLT2i is believed to be better targeted.  
The agreement and disagreement between these two new guidance documents is summarised 
in Table 1, as well as potential ways forward.  
A key area of agreement between the two is the recommendation that antihyperglycemic 
therapies that reduce CV and renal events should be offered to appropriate patients, 
regardless of the HbA1c level. SGLT2i and GLP-1RA both lower CV and renal outcomes 
independently of baseline HbA1c and of the extent of reduction in HbA1c, even if the 
mechanisms remain unclear. Although this may be misinterpreted as a “demotion” of the 
importance of glycaemic control, it is not as epidemiological, genetic and trial evidence 
supports glucose-lowering to lessen microvascular and macrovascular outcomes. The 
ADA/EASD and ESC documents continue to promote the achievement of an individualized 
glycaemic target, but not at the expense of delaying initiation of therapies that reduce clinical 
events (often in a very short time frame) in the appropriate patient. Thus, a comprehensive 
approach emerges of adding cardioprotective medications and achieving HbA1c (as well as 
cholesterol and blood pressure) targets to maximally protect patients.. 
A key area of disagreement is the primacy of metformin. Metformin is inexpensive, effective 
in lowering glucose, helpful in weight control and generally well tolerated. Metformin was 
background therapy in over 70% of the participants in the aforementioned CVOTs, but the 
benefits of the new therapies did not differ whether patients were on metformin or not.5,6 
Insisting all patients should be on metformin when there is minimal trial evidence to support 
any cardiovascular benefit in those with established ASCVD means that such patients have 
either to start two antihyperglycemic therapies simultaneously, or start metformin first then 
add a GLP-1RA or SGLT2i later. The former approach increases pill burden and the latter 
could delay the provision of medicines proven to reduce CV events. The primacy of 
metformin remains an ongoing debate that will require self-reflection to recognize how much 
the reluctance to let go of metformin is based on evidence versus sentimental loyalty. Its low 
cost and long-term safety might argue for its continued use as first line primary prevention 
therapy patients without evidence of end organ damage, although it does not have the same 
strength of evidence in showing reduction in ASCVD in these individuals as GLP-1 RAs (or 
reduction in heart failure as SGLT2 inhibitors do).   
A third point of note is placement of GLP-1RA as the preferred option for patients with 
established ASCVD in the ADA/EASD update, on the basis that MACE is a more common 
outcome and the perception that GLP-1RA reduce MACE more consistently than SGLT2i do. 
This differs from the ESC guidelines. Direct comparison of GLP-1RA and SGLT2i is not 
possible as there have been no head-to-head outcome trials. Whilst the individual components 
for MACE appear more consistently reduced with the positive GLP-1RA studies, SGLT2i’s 
also reduced overall MACE, as well as hospitalization for heart failure and hard renal 
outcomes4 – the GLP-1RA’s do not do the latter convincingly.7 Yet heart failure and renal 
failure are clearly important and some patients may prefer an oral medication. Therefore, 
even though oral GLP-1RA is now available, the decision to choose one class over the other 
in any patient with diabetes and ASCVD is complex. Perhaps, a risk calculator that estimates 
the likelihood of each of these key outcomes (MI, stroke, CVD death, heart failure, CKD) 
could be developed to help guide choice of therapy. For the time being, both drugs appear 
viable options in patients with existing ASCVD and shared decision-making with the patient 
should determine the selection on a case-by-case basis.  
Fourth, the largest and arguably the most contentious discrepancy between the updated 
ADA/EASD consensus report and the ESC guidelines, are the different definitions of 
high/very high CV risk patients. As noted above the ADA/EASD consensus report criteria are 
quite specific, whereas those advocated by the ESC are far less so, encompassing a 
substantially larger proportion of patients with T2D, many with a low absolute risk of MACE. 
The ESC criteria seem to be adapted from those originally developed to identify patients for 
treatment with LDL and blood pressure lowering therapy and include individuals with ≥3 risk 
factors (from age, hypertension, dyslipidaemia, smoking or obesity). Strict adoption of the 
ESC guidelines would mean a substantial widening in use of these newer classes, leading to 
considerable increases in drug expenditure that may not be feasible in many healthcare 
systems. We believe this substantial broadening of use needs more discussion. The potential 
use of risk scores to better target treatment needs investigation, coupled with formal cost 
effectiveness analyses.  
Finally, the ADA/EASD update recommends SGLT2i specifically for those patients with 
reduced ejection fraction HF (HFrEF) and patients with eGFR 30-60 ml/min/1.73m2 or 
UACR > 30mg/g. The renal criteria seem sensible on the basis of CREDENCE8 and health 
authorities should now amend such criteria to allow wider use of SGLT2i’s. The 
recommendation for HFrEF is appropriate on the basis of DAPA-HF,9 which showed that 
SGLT2i are effective in treating as well as preventing HF. Prospective trials will soon report 
whether SGLT2i’s also reduce risk in patients with heart failure and preserved ejection 
fraction (HFpEF).  
In summary, interest in the cardiology community in these new classes of drugs is increasing, 
brought about by the consistency of outcome benefits in recent trials. Yet, two algorithms, 
one led by the diabetes community, ADA/EASD, and the other by the cardiology community, 
ESC, are in the public domain and differ in important respects, even if they agree on others. 
This situation will lead to confusion on key points for primary care and between-specialty 
debates. Such discordance may promote the perception that even the experts cannot agree on 
the evidence which can lead to suboptimal care. We believe that diabetes, cardiology and 
nephrology experts need to come together to create a unified approach, something that would 
benefit both health care professionals and their patients.  
 
Table 1. Comparing and contrasting key elements between the new ADA/EASD consensus 











Implied but not 
explicitly stated 
Future recommendations should clearly state 
that there is strong evidence that benefit of 





first line except 
when 
contraindicated 
Yes For most but not 
necessarily in drug 
naïve patients with 
ASCVD or high or 
very high risk 
Given lack of evidence that metformin reduces 
CV events, first-line treatment with a SGLT2i or 
GLP-1RA in drug naïve patients, or add-on 
SGLT2i or GLP-1RA therapy in those already 
treated with metformin, should be recommended 
in patients with established ASCVD (and 
SGLT2i in those with CKD or HFrEF). Also in 
selected individuals at very high risk of ASCVD 
events, HF and CKD. 
 










SGLT2i or GLP-1RA: both lessen overall 
MACE to broadly similar extents. SGLT2i also 
reduced hHF and renal outcomes. Only head-to-
head trials can provide the robust evidence 
needed to recommend a preference for one over 
the other. In the meantime, new risk scores 
estimating absolute risks of individual outcomes 
in this population could aid clinical decisions as 
SGLT2i protect more against cardiorenal 
outcomes, whereas GLP-1RA protect more 
against atherothrombotic outcomes. GLP-1RA 







for SGLT2i or 
GLP-1RA  
Very specific 
(Age ≥ 55 yr 









with evidence of 
microvascular end-
organ damage, long 
duration of disease 
or multiple risk 
factors, based on 
DECLARE and 
CANVAS 
The ADA/EASD criteria are MACE centric and 
conservative; the ESC-led criteria would 
substantially expand number of eligible patients 
and costs. As drug costs decline, such issues will 
become less important but for now, targeting 
therapies to those at higher absolute risks/ end 
organ damage would seem sensible. Risk scores 
and cost effectiveness analyses may help in 
targeting therapies to those most likely to get a 
worthwhile benefit.   
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GLP-1RA may be better for those with 
coronary, carotid, lower extremity artery 
stenosis > 50% to prevent MACE but as LVH is 
stronger risk factor for HF, SGLT2i may be 
better. Future risk scores in diabetes patients 
calculating absolute risk for each of MACE, HF 
and CKD might help in choice of therapy. 
Potential value of NT-pro BNP testing also 










Treat HFrEF.  
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